DAX25.104 -0,6%Est506.121 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,5500 -3,9%Nas22.886 +0,9%Bitcoin56.296 -1,5%Euro1,1758 -0,1%Öl71,97 +0,4%Gold5.155 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F Rheinmetall 703000 SAP 716460 NVIDIA 918422 Bayer BAY001 Deutsche Telekom 555750 Siemens Energy ENER6Y Infineon 623100 Amazon 906866 Lufthansa 823212 Allianz 840400 Microsoft 870747 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schwächer -- Trump will Zollsatz weiter erhöhen -- Bitcoin, Ether & Co. sinken -- Bayer, Novo Nordisk, Rüstungsaktien, Samsung, NVIDIA, SAP, VW, Gold, Silber im Fokus
Top News
Börse am Montag: DAX zum Wochenstart tiefer - Zoll-Unsicherheit kehrt zurück Börse am Montag: DAX zum Wochenstart tiefer - Zoll-Unsicherheit kehrt zurück
Strategy-Aktie: Tipps vom Gründer - So übersteht man einen Bitcoin-Bärenmarkt Strategy-Aktie: Tipps vom Gründer - So übersteht man einen Bitcoin-Bärenmarkt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

NovoCure Aktie

Kaufen
Verkaufen
NovoCure Aktien-Sparplan
9,48 EUR -0,16 EUR -1,62 %
STU
11,35 USD -0,04 USD -0,31 %
BTT
NovoCure jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,08 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA140ML

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINJE00BYSS4X48

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVCR

NovoCure Aktien News

DatumMeistgelesen
PR NewswireNVCR DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important August 18 Deadline in Securities Class Action - NVCR
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of NovoCure Limited of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 18, 2023 - (NASDAQ: NVCR)
BusinesswireNovocure Reports Second Quarter 2023 Financial Results
BusinesswireNovocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
PR NewswireNVCR LAWSUIT ALERT: Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
PR NewswireROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
BusinesswireNovocure to Report Second Quarter 2023 Financial Results
PR NewswireNOVOCURE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Again...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
PR NewswireCalling all investors in NovoCure Limited (NVCR): New lawsuit lead plaintiff deadline is August 18, 2023 - contact Bronstein, Gewirtz & Grossman, LLC today
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
BusinesswireNovocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
BusinesswireNovocure Reports First Quarter 2023 Financial Results
BusinesswireNovocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
BusinesswireNovocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
BusinesswireNovocure to Report First Quarter 2023 Financial Results
BusinesswireKristin Stafford Joins Novocure Board of Directors
BusinesswireNovocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
BusinesswireNovocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
BusinesswireNovocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
BusinesswireNovocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
BusinesswireAllyson J. Ocean, M.D., Joins Novocure Board of Directors

NovoCure News

NovoCure News: auf dieser Seite finden Sie alle NovoCure News und Nachrichten zur NovoCure Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NovoCure News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NovoCure News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.